-
1
المؤلفون: Laura Kowalczuk, Francine Behar-Cohen, Richard F. Spaide, Alejandra Daruich, Alexandre Matet, Ali Dirani, Irmela Mantel, Aude Ambresin, Natacha Turck
المصدر: Retina (Philadelphia, Pa.)
Retina, vol. 37, no. 12, pp. 2226-2237
Retina, Vol. 37, No 12 (2017) pp. 2226-2237مصطلحات موضوعية: Male, Placental growth factor, retina, Time Factors, Visual acuity, genetic structures, Drug Resistance, Visual Acuity, Angiogenesis Inhibitors, chemistry.chemical_compound, 0302 clinical medicine, Original Study, Aged, Angiogenesis Inhibitors/administration & dosage, Bevacizumab/administration & dosage, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Intravitreal Injections, Middle Aged, Receptors, Vascular Endothelial Growth Factor/administration & dosage, Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors, Recombinant Fusion Proteins/administration & dosage, Retina/pathology, Retinal Telangiectasis/diagnosis, Retinal Telangiectasis/drug therapy, Retrospective Studies, Tomography, Optical Coherence/methods, Treatment Outcome, Macular telangiectasia, Aflibercept, macular telangiectasia, aflibercept, General Medicine, Diabetic retinopathy, 3. Good health, Bevacizumab, Vascular endothelial growth factor, 030220 oncology & carcinogenesis, medicine.symptom, Tomography, Optical Coherence, medicine.drug, medicine.medical_specialty, Recombinant Fusion Proteins, 03 medical and health sciences, Ophthalmology, medicine, ddc:576, business.industry, medicine.disease, eye diseases, Surgery, Receptors, Vascular Endothelial Growth Factor, chemistry, 030221 ophthalmology & optometry, Retinal Telangiectasis, sense organs, Ranibizumab, business
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::152971000b9e76158e1f8fda4a9d0b7d
https://doi.org/10.1097/iae.0000000000001424 -
2
المؤلفون: Ciara Bergin, Irmela Mantel, Parmis Parvin, Sophie de Massougnes, Marta Zola, Ali Dirani
المصدر: Retina, vol. 39, no. 5, pp. 906-917
مصطلحات موضوعية: medicine.medical_specialty, genetic structures, business.industry, Incidence (epidemiology), Macular atrophy, General Medicine, Macular degeneration, medicine.disease, eye diseases, Ophthalmology, Regimen, medicine, sense organs, Dosing, Ranibizumab, Risk factor, business, medicine.drug, Aflibercept, Aged, Angiogenesis Inhibitors/administration & dosage, Angiogenesis Inhibitors/adverse effects, Atrophy/chemically induced, Atrophy/diagnosis, Atrophy/epidemiology, Disease Progression, Dose-Response Relationship, Drug, Female, Fluorescein Angiography, Fundus Oculi, Humans, Incidence, Intravitreal Injections, Macula Lutea/drug effects, Macula Lutea/pathology, Male, Prognosis, Prospective Studies, Ranibizumab/administration & dosage, Ranibizumab/adverse effects, Receptors, Vascular Endothelial Growth Factor/administration & dosage, Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors, Recombinant Fusion Proteins/administration & dosage, Recombinant Fusion Proteins/adverse effects, Risk Factors, Switzerland/epidemiology, Tomography, Optical Coherence, Visual Acuity, Wet Macular Degeneration/diagnosis, Wet Macular Degeneration/drug therapy
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b82ce6d7f1abe3bf1d6256ea32c6e37e
https://serval.unil.ch/resource/serval:BIB_160E4E5271F0.P001/REF.pdf -
3
المؤلفون: Sherman, Si, Wirth, Lj, Droz, Jp, Hofmann, M, Bastholt, L, Martins, Rg, Licitra, L, Eschenberg, Mj, Sun, Yn, Juan, T, Stepan, De, Schlumberger, Mj, Motesanib Thyroid Cancer Study Group including Lind, P, Pirich, C, Daumerie, C, Baudin, E, Bui, Bn, Conte Devolx, B, Rohmer, V, Schvartz, C, Szabolcs, I, Racz, K, Brandi, Ml, Pinchera, A, Elisei, R, Orlandi, Fabio, Pacini, F, Jarzab, B, Sowinski, J, Jansson, S, Lundell, G, Hallqvist, A, Meier, C, Philippe, J, Agarwala, S, Ali, H, Barrera, J, Boccia, R, Bukowski, R, Burman, K, Clark, O, Davis, T, Hoff, A, Sarlis, N, Jakub, J, Mena, R, Nahleh, Z, Rosen, L, Stephenson, J, Srkalovic, G, Tchekmedyian, N.
المصدر: New England Journal of Medicine, Vol. 359, No 1 (2008) pp. 31-42
Sherman, S I, Wirth, L J, Droz, J-P, Hofmann, M, Bastholt, L, Martins, R G, Licitra, L, Eschenberg, M J, Sun, Y-N, Juan, T, Stepan, D E, Schlumberger, M J & Study Group, M T C 2008, ' Motesanib diphosphate in progressive differentiated thyroid cancer ', The New England Journal of Medicine, vol. 359, no. 1, pp. 31-42 . https://doi.org/10.1056/NEJMoa075853مصطلحات موضوعية: Adenoma, Oxyphilic/drug therapy/secondary, Male, Indoles, Thyroid Neoplasms/drug therapy/genetics/pathology, medicine.medical_treatment, Oligonucleotides, Gastroenterology, Motesanib Diphosphate, chemistry.chemical_compound, Adenocarcinoma, Follicular, Motesanib, thyroid cancer, Adenoma, Oxyphilic, Thyroid cancer, ddc:616, Aged, 80 and over, Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors, General Medicine, Middle Aged, Proto-Oncogene Proteins c-kit, Niacinamide, Disease Progression, Adenocarcinoma, Female, Mitogen-Activated Protein Kinases, Adult, medicine.medical_specialty, Adenocarcinoma, Follicular/drug therapy/secondary, Genotype, Antineoplastic Agents, Antineoplastic Agents/adverse effects/therapeutic use, Thyroglobulin, Niacinamide/adverse effects/analogs & derivatives/therapeutic use, Thyroid carcinoma, Text mining, Internal medicine, medicine, Biomarkers, Tumor, Humans, Thyroid Neoplasms, Survival analysis, Aged, Thyroglobulin/blood, business.industry, Disease progression, Cancer, medicine.disease, Survival Analysis, Carcinoma, Papillary, Carcinoma, Papillary/drug therapy/secondary, Receptors, Vascular Endothelial Growth Factor, Endocrinology, chemistry, Indoles/adverse effects/therapeutic use, Cancer research, business, Progressive disease